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1. Introduction 
Overactive bladder (OAB) is a disturbance of filling/storage and has been defined by the 
International Continence Society as “a symptom syndrome consisting of urgency with or 
without urge urinary incontinence, often associated with urinary frequency and nocturia.” 
(Abrams et al., 2002) OAB has been divided into OAB without urinary incontinence 
(OABdry) and OAB with urinary incontinence (OABwet). The reported prevalence of OAB in 
women varies between 7.7 and 31.3%, and increases with age. (Irwin et al., 2006a; McGother 
et al., 2006;Milsom, et al., 2001; Stewart et al., 2003; Wagg et al., 2007) 
The symptoms of OAB include urinary urgency, urinary frequency, nocturia, and urinary 
urge incontinence. These symptoms often remain undetected and undertreated by both the 
woman and her providers, despite the substantial impact on a woman's quality of life. 
(Griffiths et al., 2006; Mardon et al., 2006) In a multiethnic survey, only 45 percent of women 
who reported weekly urinary incontinence sought care for their incontinence symptoms. 
(Harris et al., 2007) This leaves incontinent women with psychological morbidity and a 
diminished quality of life. (Irwin et al., 2006b)  
2. Etiology 
2.1 Normal micturition 
The normal micturition cycle includes inhibition and contraction of detrusor smooth muscle, 
afferent signaling from the urothelium, contraction and relaxation of the smooth and 
striated sphincter muscles, and the central, peripheral, and autonomic nervous systems. 
Urine storage occurs secondary to afferent signals stimulated by bladder filling. These 
afferent signals activate sympathetic pathways in the hypogastric and pudendal nerves, 
which lead to contraction of the smooth and striated sphincters, and at the same time inhibit 
detrusor contraction. In addition, high cortical centers are activated, (Griffiths et al, 2007), 
and stimulate the storage center in the pons. (Fowler et al, 2008) When further bladder 
filling leads to increased afferent signaling from the bladder, spinobulbospinal reflex 
pathways are carried via the pelvic nerve and spinal cord to the pontine micturition center, 
which activates parasympathetic pathways that cause bladder contraction and inhibit 
sympathetic and pudendal contraction of the sphincter (Fowler et al, 2008)  
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For coordinated micturition to occur, parasympathetic stimulation of the detrusor occurs via 
cholinergic muscarinic receptors. Urethral smooth muscle contraction occurs chiefly by 
stimulation of alpha-adrenerigic receptors. (Fowler et al, 2008) In addition, a variety of 
neurotransmitter systems in the urothelial lining of the bladder and in bladder interstitial 
cells likely play a role in mediating bladder contraction and relaxation via afferent signaling. 
(Andersson, 2002) This complex interplay results in socially appropriate and effective 
voiding. Any disruption in this pathway can lead to storage and/or emptying disorders. 
Bladder overactivity may be related to neurogenic, myogenic, or idiopathic origins. 
2.2 OAB etiology 
The presumed etiology of OAB is uninhibited bladder contractions, but overactivity is not 
sufficient to cause incontinence (e.g. OABdry). In addition, leakage symptoms may be due to 
factors outside of the lower urinary tract such as failure of compensatory mechanisms in the 
lower urinary tract (e.g. fascial and muscular urethral support "hammock" that compresses 
the urethra when there is increased abdominal pressure or when the pelvic muscles are 
contracted) , and functional impairments in some patients.  
2.2.1 Neurogenic etiologies 
2.2.1.1 Suprapontine lesions 
Patients with suprapontine lesions such as cerebrovascular disease and Parkinson’s disease 
can present with detrusor overactivity. These patients lose voluntary inhibition of 
micturition most likely secondary to uninhibited detrusor contractions. (Fall, et al, 1989) 
(Fall, et al, 1995) The cerebral cortex and the basal ganglia are theorized to suppress the 
micturition reflex. Therefore, damage to the brain results in bladder overactivity by 
reducing suprapontine inhibition. (Koelbl et al, 2009) 
2.2.1.2 Spinal cord lesions 
Spinal cord disruption below the level of the pons leads to unsustained and uncoordinated 
detrusor contractions. (Koelbl et al, 2009) Impairment or loss of bladder sensation usually 
occurs. Patients with spinal cord lesions above the lumbosacral level lose voluntary and 
supraspinal control of micturition. Bladder overactivity in these patients is mediated by 
spinal reflex pathways (deGroat et al, 1993) (Bros & Comarr,1971) 
2.2.2 Non-neurogenic etiologies 
2.2.2.1 Outflow obstruction 
Outflow obstruction is associated with detrusor overactivity. (Koelbl et al, 2009) Up to 50% 
of patients with symptomatic benign prostatic enlargement exhibit bladder outlet 
obstruction. ( de Nunzio et al, 2003) However, OAB symptoms can occur independently of 
bladder outlet obstruction. One hypothesis that has been proposed to explain how outflow 
obstruction causes OAB and detrusor overactivity includes partial denervation.  
Denervation injury has been shown to increase detrusor supersensitivity to acetylcholine. 
(Harrison et al, 1987) This may be the basis of unstable bladder activity. However, it is not 
clear how denervation develops in patients with outflow obstruction. It is possible that there 
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is a reduction of blood flow due to increased intravesical pressure during voiding or the 
increased tissue pressure of hypertrophied bladder wall during filling. (Azadzoi et al, 1996) 
(Greenland & Brading, 2001) 
2.2.2.2 Aging 
The prevalence of OAB in both men and women increases with age. In addition, storage 
symptom scores increase with age while bladder compliance decreases. (Koelbl et al, 2009) 
This implies that bladder function in both sexes has age related alterations. (Araki et al, 
2003) There can be difficulty however, in determining in the elderly, the difference between 
neurogenic and non-neurogenic causes.  
2.2.2.3 Estrogen deficiency 
Menopause and estrogen deficiency have been implicated in the etiology of OAB symptoms. 
(Koelbl et al, 2009) Estrogen receptors (ERs) have been identified in the bladder and urethra. 
(Blakeman et al, 2000) The effect estrogen has on bladder contractility has yet to be elucidated.  
However, it has been shown that estrogen replacement therapy can significantly improve 
the symptoms of frequency, urgency and urge incontinence. (Eriksen & Rasmussen,1992) In 
addition, a metaanalysis of the effects of estrogen therapy on symptoms of OAB in 
postmenopausal women showed that estrogen therapy was associated with significant 
improvements in all symptoms of OAB. (Cardoza et al, 2004b) Thus it appears that 
menopause plays role in the development of bladder overactivity and OAB symptoms in 
women.  
2.2.3 Idiopathic etiologies 
Idiopathic detrusor overactivity is a diagnosis of exclusion of all other known causes. 
Mechanisms that have been proposed for idiopathic detrusor overactivity include myogenic, 
urothelial and muscarinic. 
2.2.3.1 Myogenic  
Mills et al, noted that denervation is consistently found in detrusor biopsies from patients 
with non-neurogenic detrusor overactivity. (Mills et al, 2000) They hypothesize that partial 
denervation of the detrusor alters the properties of smooth muscle, which leads to increased 
excitability and increased coupling between cells. Thus, myogenic changes in the bladder 
increase contractility locally.  
2.2.3.2 Urothelial  
Another mechanism that has garnered interest in idiopathic detrusor overactivity is the 
roles of the urothelium and suburothelial myofibroblasts in afferent activation. The C-fiber 
afferents have endings in the suburothelial layer of the bladder wall, and may reach the 
urothelium. (Koelbl et al, 2009) Upon bladder distention ATP has been shown to be released 
from the urothelium. (Ferguson et al, 1997) ATP receptors on afferent nerve terminals are 
stimulated by ATP release to evoke a neural discharge. It has been proposed that there is 
up-regulation of the afferent activation mechanisms(eg. an increased generation/release of 
ATP increased sensitivity of afferent nerves to mediators, increased number of afferent 
nerves) can cause the symptoms of OAB. (Koelbl et al, 2009)  
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2.2.3.3 Muscarinic  
As stated above, muscarinic receptors play a significant role in OAB. ATP, Acetylcholine 
(Ach) and other “signaling molecules, interact with the afferent nerve fibers under the 
urothelium. Bladder distention presumably causes release of Ach (and other molecules) to 
stimulate muscarinic receptors on myofibroblasts(predominantly M2). (Mansfield et al 2005) 
It appears that an increase in Ach release from the urothelium and/or upregulation of 
muscarinic receptors in the urothelium as well as in suburothelial myofibroblasts may 
increase afferent nerve activity and contribute to the development of detrusor overactivity. 
(Koelbl et al, 2009)  
3. Clinical presentation  
Women with OAB may experience urinary urgency at inconvenient and unpredictable 
times. Urgency is the complaint of a sudden compelling desire to pass urine which is 
difficult to defer. In addition, patients may experience increased 24-hour frequency 
defined as the total number of daytime voids and episodes of nocturia during a specified 
24 hours period. Daytime frequency is defined as the number of voids recorded during 
waking hours and includes the last void before sleep and the first void after waking and 
rising in the morning. Both frequency and urgency may occur and urine leakage may 
occur prior to reaching a toilet. These symptoms interfere with work, activities of daily 
life, intimacy, and sexual function, and they can also cause embarrassment and 
diminished self-esteem. (Shaw & Burrows, 2011) Many patients with OAB have symptoms 
that wake them up at night. Nocturia is the complaint that the individual has to wake at 
night one or more times to void.  
4. Diagnosis 
The presumptive diagnosis of OAB can usually be made in the primary care provider’s 
office. Patients who present with the symptoms of urinary urgency and frequency can be 
evaluated utilizing standardized questionnaires, bladder diaries, a thorough history and 
physical examination, and simple laboratory tests. Those patients with more complex 
presentations may require urodynamic studies to confirm the diagnosis of OAB or detrusor 
overactivity.  
4.1 Symptom and quality of life questionnaires 
One of the most important aspects of the patient’s history is to establish the impact of 
symptoms on their lives. This will guide the rest of the evaluation and subsequent treatment 
decisions. Most of the currently used symptom scales focus on patient-perceived frequency 
of symptoms and how much bother the symptoms cause. (Basra et al., 2007; Coyne et al., 
2005a; Coyne et al., 2005b) Some newer validated scales have been developed which target 
more specific aspects of OAB. One of these, the OAB symptom score, is a 7-item 
questionnaire that records all the symptoms of OAB using consistent terminology. (Blaivas 
et al., 2007) Additionally, the International Continence Society (ICS) have established 
questionnaires (eg International Consultation on Incontinence Modular Questionnaire 
(ICIQ)) (Abrams et al, 2009)) 
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4.2 Bladder diaries 
Bladder diaries are an excellent tool that can be utilized to assess the frequency of daytime 
and nighttime voiding, as well as the timing of incontinence episodes and pad usage. 
Recently, bladder diaries have been developed that reliably assess the rate and severity of 
urinary urgency and are readily available. (Abrams et al, 2009) Despite some limitations, 
bladder diaries do provide a baseline with which to compare treatment efficacy. 
4.3 History 
A thorough history should inquire about the onset, duration, severity, and bother of lower 
urinary tract symptoms. In addition, a medical, surgical, gynecological, and obstetrical 
history should be obtained. Inquire about current medications which affect bladder 
function, particularly diuretics, alcohol, caffeine, narcotics, and calcium channel blockers. 
4.4 Physical Examination 
The physical examination should be focused on the abdominal and genitourinary 
examinations. The pelvic examination is used to evaluate the strength of the muscles of the 
pelvic floor and to assess for pelvic organ prolapse, urethral mobility, and stress urinary 
incontinence. The rectal examination is used to assess for any masses and to evaluate for 
constipation and anal tone. A simple, focused neurologic examination to evaluate pelvic 
reflexes, innervation of the lower extremities, and the patient's mental status completes the 
physical examination. 
4.5 Urinalysis 
Because some patients who present with acute symptoms of frequency and urgency have a 
urinary tract infection, a urinalysis (UA) is performed. In addition a UA will detect 
hematuria or glucosuria. 
4.6 Postvoid residual 
A post-void residual (PVR) is performed as a rough evaluation of as a measurement of the 
efficiency of evacuation of the bladder. This can be measured by bladder ultrasonography or 
post-void catheterization. Although there is no universally accepted definition of an 
abnormally elevated PVR, a high post-void residual (greater than 100 cc) may be cause for 
further, more complex testing. In addition, patients with high PVR’s are at high risk for 
urinary retention, especially when anticholinergic medications are prescribed.  
4.7 Urodynamic studies 
Urodynamic studies can provide additional insight into bladder pathophysiology and can 
be a key to making the diagnosis of OAB and destrusor overactivity. Urodynamic studies 
are a series of clinical tests, such as flow studies, filling cystometry, pressure-flow studies 
and/or urethral function measurements. These can be combined with electromyography 
(EMG) recording and/or imaging by either X-rays or ultrasound. (Abrams et al, 2009) 
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The goal of urodynamic studies is to reproduce the symptom(s) of the patient under 
controlled and measurable conditions. According to the 4th International Consultation on 
Continence (Abrams et al, 2009) the role of urodynamic studies can be: 
 To identify or to rule out factors contributing to the lower urinary tract(LUT) 
dysfunction To obtain information about other aspects of LUT dysfunction 
 To predict the consequences of LUT dysfunction for the upper urinary tract 
 To predict the outcome, including undesirable side effects, of a contemplated treatment 
 To confirm the effects of intervention or understand the mode of action of a particular 
type of treatment 
 To understand the reasons for failure of previous treatments for urinary incontinence, 
or for LUT dysfunction in general. 
In addition to recommending the role of urodynamic studies, The International Continence 
Society (ICS) has provided standards for urodynamic terminology and techniques (Abrams, 
2002) For example, urodynamic detrusor overactivity is defined by the ICS as “Loss of urine 
as a result incontinence of involuntary detrusor activity during the storage phase of 
urodynamic testing. 
Following is a brief description of the most commonly used urodynamic studies. 
4.7.1 Uroflowometry 
Uroflowometry is a non-invasive measurement of urine flow rate. The patient urinates into a 
flow meter in private. (Schafer,2002) The flow rate is measured and displayed graphically. The 
volume voided, shape of the curve and the maximum flow rate are automatically graphed. 
These parameters determine if the patient is emptying their bladder normally. When an 
abnormal recording is obtained, it is best to repeat the assessment for reproducibility.  
4.7.2 Filling cystometry 
Filling cystometry is an invasive measurement of the pressure inside the bladder to assess 
its storage capabilities. It involves placing a pressure sensor into the bladder and another 
pressure sensor rectally or vaginally to measure abdominal pressure. A computer subtracts 
the abdominal pressure from the bladder pressure to provide the clinician with a graphic 
representation of pressure changes due to the true detrusor muscle. The bladder is usually 
filled with normal saline through the transurethral filling channel of a dual lumen catheter. 
The filling rate is usually controlled by a computer and the intravesical abdominal and 
detrusor pressure are monitored graphically. The storage ability of the bladder is assessed 
and presented graphically in terms of the volumes required to elicit various bladder 
sensations from the patient, its capacity, its compliance and its stability. The filling (storage) 
phase of cystometry is also the only method of demonstrating urodynamic stress 
incontinence (USI). (Abrams et al, 2009) 
4.7.3 Pressure-flow studies (Voiding cystometry) 
Voiding cystometry is a measurement of the mechanics of micturition. Generally this study 
is performed after bladder filling during cystometry is complete. While monitoring 
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intravesical, abdominal and detrusor pressures, the patient is allowed to void and empties 
their bladder on a flow meter. Measurement of both flow rate and pressure allows voiding 
to be assessed. In patients whose bladder emptying is poor, it may determine if poor flow is 
due to outflow obstruction or poor detrusor contractility.  
4.7.4 Urethral pressure profilometry 
Urethral pressure profilometry is a test that measures the urethra’s ability to maintain 
pressure along its length. This test is performed by placing a pressure sensor transurethrally 
into the bladder and usually withdrawing it along the urethra by a mechanical puller at a 
constant rate. The pressure along the length of the urethra is measured and graphically 
represented. The maximum pressure measured in the urethra gives an indication of the 
closure function of the urethra. 
4.7.5 Abdominal leak point pressure 
Similar to urethral pressure profilometry, abdominal leak point pressure is used as a 
measure of the urethra’s ability to act as a valve to store urine. Intravesical or abdominal 
pressure is assessed while the patient is asked to increase their abdominal pressure by 
valsalva or by coughing. The abdominal pressure at which the patient leaks urine gives a 
measure of the closure pressure of the urethra. The greater the pressure required to produce 
leakage, the better the closure function of the urethra.  
5. Management 
The most commonly used measure of urinary incontinence (UI) treatment efficacy is a 
reduction in urinary incontinence episodes. Generally, this is recorded as the reduction in 
mean number of daily episodes, percent reduction from baseline, or reduction in leakage 
volume. Other outcome measures commonly used for OAB are urinary frequency (total 
number of daytime and nighttime voids) and frequency of urgency symptoms (with or 
without leakage). Cure is usually defined as complete absence of urinary incontinence. 
(Abrams, 2009) 
One of the most important measures from the patient’s perspective is quality of life. In the 
literature, many investigations measure patient perception of improvement of OAB, general 
satisfaction questions, and urinary incontinence-specific quality of life measures. The ICS 
recommends using patient reported outcome questionnaires that have been rigorously 
evaluated. (Koelbl et al, 2009) 
5.1 Conservative therapies 
Once the diagnosis of OAB has been made, the combination of dietary and lifestyle 
modification, bladder training, pelvic floor muscle training (PFMT), and biofeedback should 
be recommended as the initial intervention for OAB. (Burgio, 2002) The Agency for Health 
Care Policy and Research as well as the Third International Consultation on Incontinence 
recommends behavioral therapy as first-line therapy. (Wilson et al., 2005) The advantages of 
behavioral methods include avoidance of surgery, improved central control of bladder 
function and no adverse drug reactions. 
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5.1.1 Dietary and lifestyle modification 
A common sense approach to the treatment of patients with OAB should include counseling 
patients on dietary and lifestyle modification that may improve their symptoms and quality 
of life. In general, patients should increase awareness of amounts and types of fluids 
consumed, especially as it relates to their symptoms. Although not well studied some foods 
and beverages are believe to increase detrusor activity and symptoms of OAB. The authors 
recommend that patient’s begin to eliminate one food or beverage at a time from the 
following list: 
 Beverages 
 Alcoholic 
 Caffeinated (Coffee, Tea) 
 Carbonated 
 Foods 
 Tomatoes and tomato-based products 
 Spicy foods 
 Citrus juice and fruits 
 Artificial sweeteners 
 Chocolate 
 Corn syrup 
 Sugar 
 Honey 
In one study patients with caffeine intake > 400 mg/day were shown to be 2.4 times more 
likely to have detrusor overactivity. (Arya, et al., 2000) In addition, limiting fluid intake has 
been shown to reduce frequency and urgency as well as improve quality of life in patients 
with OAB. (Milne, 2008 and Swithinbank et al., 2005)  
Although weight loss is a good lifestyle modification, in general, it has been shown to 
significantly improve only stress urinary incontinence symptoms, but not OAB symptoms. 
A large randomized trial of overweight and obese women with urinary incontinence 
symptoms underwent an intensive 6 month weight loss program compared to a group with 
a structured education program. (Subak et al., 2009) Mean weight loss was 8 percent (7.8 kg) 
and 1.6 percent (1.5 kg) in the intervention and control groups, respectively. The authors 
found that weekly incontinence episodes decreased by 47 percent in the intervention group 
compared to only 28 percent in the control group. Of note, is that these patients had a 
significant decrease in stress incontinence, but not urge incontinence episodes. 
5.1.2 Bladder retraining 
Bladder training involves patient education and scheduled voiding in which the voiding 
interval is progressively increased. This method is based upon frequent voluntary voiding 
which keeps the bladder volume low and training the central nervous system on pelvic floor 
musculature to inhibit urgency. Utilizing the patient’s bladder diary, the initial frequency of 
timed voiding is based on the smallest time interval between voids. The goals of bladder 
training are to normalize urinary frequency, to improve control over bladder urgency, to 
increase bladder capacity, to decrease incontinence episodes, to prolong voiding intervals, 
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and to improve the patient's confidence in bladder control. It is safe and may be beneficial. 
(Wallace et al., 2004) Bladder training requires compliant and motivated patients and may 
not be suitable for those with cognitive impairment. It can be time-consuming and is 
primarily effective during waking hours. (Ouslander et al., 2001) 
Patients can be instructed to follow the steps listed below for bladder training :(Modified 
from DuBeau, 2011):  
 Go to the toilet and try to pass urine every two hours while you are awake.  
  You do not have to get up during the night! 
 You must try to pass urine whether you feel the need or not 
 You must try to pass urine even if you have just been incontinent. 
  If you get a strong urge to go to the bathroom before your scheduled time: 
 Stop, don't run to the bathroom! 
 Stand still or sit down if you can. 
 RELAX. Take a deep breath and let it out slowly. 
 Concentrate on making the urge decrease or even go away, anyway you can. 
 When you feel in control of your bladder, walk slowly to the bathroom, and then 
go. 
 Keep this schedule until you can go two days without urine leakage.  
 Then, increase the time between scheduled trips to the toilet by one hour 
 When you can go two days without urine leakage, extend the time between trips 
again. 
 Keep this up until you can go four hours between trips to the toilet, or until you are 
comfortable.  
 This may take several weeks. 
 DON'T GET DISCOURAGED! Bladder training takes time and effort, but it is an 
effective way to get rid of incontinence without medication or surgery 
A review in 2009 found that bladder training may be helpful for the treatment of urinary 
incontinence, but definitive research is needed to support that conclusion. (Wallace et al., 
2004) However, there is very little downside to this therapy.  
5.1.3 Pelvic floor muscle training (PFMT) 
PFMT involves exercises designed to improve the function of the pelvic floor muscles. Using 
PFMT to treat OAB is based on the theory that contraction of the levator ani muscles can 
reflexively inhibit contraction of the detrusor muscle. PFMT is defined as any program of 
repeated voluntary pelvic floor muscle contractions (VPFMC) taught by a trained healthcare 
professional. (Wilson et al., 2005) Patients are taught to squeeze the pelvic floor with three 
sets of 8 to 12 slow velocity contractions held for six to eight seconds each. These exercises 
should be performed at least three or four times a week and continued for at least 15 to 20 
weeks. (Hay-Smith et al., 2009) 
There is increasing evidence to support the use of PFMT for OAB. Patients with detrusor 
overactivity who completed a PFMT program experienced a clinically and statistically 
significant reduction in daily UI episodes. (Ba & Berghmans, 2000 and Nygaard et al., 1996) 
These investigators also reported a significant decrease in urge score. This urge score was 
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defined as the frequency of leakage (0 = never to 4 = always) during 9 activities that can 
trigger urge incontinence. 
5.1.4 Weighted vaginal cones 
Patients may have additional improvement in learning to appropriately do PFMT with the 
use of vaginal weighted cones. These cones are inserted in the vagina by the patient and she 
learns to contract the pelvic floor muscles to hold the cone in place.  
5.1.5 Biofeedback 
Biofeedback is used to teach patients how to control normal physiologic responses of the 
bladder and pelvic floor muscles that mediate urinary incontinence. Biofeedback for OAB 
consists of bladder-pressure biofeedback as well as the pelvic floor's muscular activity 
feedback. (Burgio et al., 1985)  
5.1.6 Limitations of behavioral therapy 
Behavioral therapy requires the active participation of motivated patients and a practitioner 
well-trained in behavioral therapy. Behavioral therapy does not cause permanent changes in 
bladder function; therefore, regular adherence and long-term compliance are needed for 
effectiveness. 
5.2 Pharmacological agents 
Traditionally, drug therapy is commenced at the same time as behavioral therapy. Drug 
treatment plays an important role in the management of women with OAB, although many 
drugs currently in use have not been subjected to controlled clinical trials in the treatment of 
OAB. From a review of the literature, it is clear that there is no ideal drug. (Hay-Smith et al., 
2005) Current pharmacological approaches to improving the treatment of OAB include 
delayed release formulations of existing oral agents, new pharmaceutical agents with 
greater specificity/selectivity, and alternative routes of administration. New generation 
pharmacological treatments provide better or comparable efficacy with fewer adverse drug 
events. (Shaw & Burrows, 2011) 
5.2.1 Antimuscarinic (anticholinergic) drugs 
There are many different antimuscarinic compounds licensed for use for patients with OAB. 
Oxybutynin was the first drug of this class used specifically to treat the symptoms of OAB. 
This class of drugs has been considered the “gold standard” in the treatment of OAB for 
many years. However, there is little or no evidence to help clinicians choose between 
particular anticholinergic drugs. To add to the difficulty with studying this class of drugs, 
compliance with antimuscarinics is generally poor. (Brubaker et al., 2010)  
Traditionally, it was thought that these drugs act by blocking the muscarinic receptors on 
the detrusor muscle. This resulted in decreased bladder contractions and thus reduced the 
symptoms of OAB. However, it appears that antimuscarinic drugs act primarily during the 
storage phase of the micturition cycle, decreasing urgency and increasing bladder capacity. 
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During this phase, there is normally no parasympathetic input to the LUT. (Abrams & 
Andersson, 2007) 
A recent Cochrane review assessed the various anticholinergics available for the treatment 
of OAB in adults. The conclusions of this review were when the prescribing choice is 
between oral immediate-release oxybutynin and tolterodine, tolterodine might be 
preferred due to a reduced risk of dry mouth. In addition, they concluded that if 
extended-release preparations of either drug are available, they would be preferred to the 
immediate-release preparations because of the decreased risk of dry mouth and better 
compliance. There were insufficient data from trials of other anticholinergic drugs to 
draw any conclusions. (Hay-Smith et al., 2005) The most commonly prescribed 
anticholinergic drugs and their dosages in the treatment of OAB are listed in Table 1. 
(Shaw & Burrows, 2011) 
5.2.1.1 Oxybutynin 
As mentioned above, oxybutynin was the first anticholinergic widely used for the treatment 
of OAB. It is an anticholinergic agent that has antimuscarinic, antispasmodic, and potential 
local anesthetic effects. Oxybutynin has been shown to have a high affinity for the M1 & M3 
receptors and much less affinity for the M2 receptor. (Hughes et al., 1992 and Nilvebrant & 
Sparf, 1986) It is available in immediate release (IR), extended release (ER), transdermal 
patch and topical gel formulations. In general, the efficacy is similar for all formulations. The 
initial dosage for IR is 2.5 mg two to three times daily, followed by titration as needed up to 
20 mg/day in divided doses. The ER formulation is started at 5 mg once daily and titrated 
up to 20 to 30 mg once daily.  
The transdermal patch (equivalent to 3.9 mg/day) applied to the abdomen, hip, or buttock 
is changed twice a week. The topical 10% gel is applied as 1 gm (approximately 1 mL) daily 
to the thigh, abdomen, upper arm, or shoulder. Currently, oxybutynin IR and ER are 
available as generic formulation in the United States. Oxybutynin IR is associated with high 
rates of anticholinergic adverse effects. Dry mouth is a particularly bothersome side effect 
for patients that can limit therapy with oxybutynin IR. This side affect is less frequent with 
the ER and transdermal preparations (Anderson et al., 1999; Davila et al., 2001; Versi et al., 
2000) Irritation and pruritus at the application site has been reported in approximately 15 
percent of patients using transdermal oxybutynin and 5 percent using the topical gel. 
(Dmochowski et al., 2002) 
5.2.1.2 Tolterodine 
Tolterodine has been shown to be a competitive muscarinic receptor antagonist with some 
selectivity for bladder muscarinic receptors [59]. It is available in immediate- and extended- 
release forms. Tolterodine is administered at 1 to 2 mg twice a day for the IR preparation or 
2 to 4 mg per day using the ER preparation. It has similar efficacy when compared to other 
antimuscarinics. Both formulations have shown efficacy for symptoms of OAB in a large 
study population (Choo et al., 2008).  
One of the few “head to head” studies between anticholinergic drugs was The STAR trial. In 
this study the investigators directly compared solifenacin (discussed below) at a flexible 5 or 
10 mg once daily dose with tolterodine extended release 4 mg once daily in a randomized 
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controlled trial. (Chapple et al., 2005) The authors found that the flexible dose of solifenacin 
showed marked advantages over the single dose of tolterodine extended release. In a 
reanalysis comparing only the patients in the trial taking solifenacin 5 mg once daily with 
the patients in the tolterodine arm the authors found a more modest benefit. (Chapple et al., 
2007) Solifenacin 5 mg once daily was superior for incontinence episodes and pad usage, but 
showed no difference in urge incontinence or dryness rates. Notably in both analyses, the 
main advantage for solifenacin was minimizing rates of dry mouth and constipation. 
However, there were slightly more withdrawals due to adverse events in the solifenacin 
group. 
5.2.1.3 Solifenacin 
Solifenacin is an antimuscarinic agent has potent selectivity for the M3 over the M2 receptor. 
(Chapple et al., 2006) In addition it has a higher affinity for the M3 receptor in smooth 
muscle than it does for the M3 receptor in the salivary gland. (Chapple et al., 2006). This M3 
selectivity provides for an improved side effect profile. Solifenacin is administered at 5-10 
mg daily for the treatment of OAB.  
It has been proven efficacious in multiple trials in patients with OAB. (Cardozo et al., 2004; 
Cardozo et al., 2008; Chapple, 2005) Another recent study confirmed that solifenacin was 
significantly more effective in reducing the mean number of severe urgency episodes with 
or without incontinence per 24 hours, improved urgency symptoms and was well tolerated. 
Additionally, no cognitive impairment has been associated with this drug. (Kay et al., 2006) 
5.2.1.4 Trospium chloride 
Trospium chloride is a quaternary ammonium compound that is nonselective for the 
muscarinic receptor. It also has smooth muscle relaxant qualities. (Staskin et al., 2007) 
Trospium chloride is available in an IR formulation given 20 mg twice daily or an ER 
formula administered 60 mg daily. The uniqueness of this antimuscarinic is that it is renally 
cleared. Care should be used in the elderly and patients with renal impairment. The initial 
dosing in these patients she be the IR formulation 20 mg once daily. The ER formulation 
should not be used in patients with severe renal impairment. Because of poor 
bioavailability, trospium chloride must be taken on an empty stomach. 
When compared to placebo, trospium chloride showed a greater decrease in the number of 
daily episodes of incontinence than patients who received placebo (from a mean of 2.9 to 1.0 
with trospium and 1.6 with placebo). (Zinner et al., 2004) Side effects in the trospium 
chloride group included dry mouth (20 percent) and constipation (11 percent). 
In a randomized trial utilizing the ER formulation (60 mg once daily) for patients with 
severe urge incontinence, patients’ incontinence episodes decreased significantly compared 
to placebo. Adverse events were lower than reported for immediate-release trospium 
chloride (dry mouth 13 percent, constipation 8 percent). (Dmochowski et al., 2008) 
5.2.1.5 Fesoterodine 
Fesoterodine is given at a starting dose of 4 mg once daily, which can be increased to 8 mg. 
As with most of the anticholinergic drugs, the most common side effects are dry mouth and 
constipation.  
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Fesoterodine is metabolized to 5-hydroxymethyl tolterodine, (the active metabolite of 
tolterodine).  
5.2.1.6 Darifenacin 
Similar to solifenacin, the newer antimuscarinic drug darifenacin is more selective for M-3 
muscarinic receptors in the bladder. Drifenacin is administered 7.5 mg daily and can be 
increased to 15 mg daily. In a randomized trial of darifenacin versus placebo, median 
incontinence episodes were show to significantly decrease with darifenacin. (Zinner et al., 
2006) However, dry mouth and constipation rates were similar when compared to other 
anticholinergics (29% dry mouth and 18% constipation).  
As noted above, the most common side effects associated with darifenacin are mild to 
moderate dry mouth and constipation. This drug has been studied in patients who were 
dissatisfied with prior OAB treatment with oxybutynin ER or tolterodine ER. The authors 
found significant improvements in OAB symptoms with darifenacin. (Zinner et al., 2008) 
Additionally, long-term studies have shown persistence of continuation with darifenacin 
therapy and well-maintained treatment benefits (over 2 years in duration). (Haab et al., 2006 
& Hill et al., 2007) 
Because of its’ selectivity for the M3 receptor darifenacin minimizes the risk of side effects 
due to blockade of other muscarinic subtypes, such as M1 mediated cognitive impairment. 
(Foote et al., 2005) This is important in relation to the treatment of elderly populations who 
may be more susceptible to cognitive impairment and CNS effects.  
 
Generic name Brand Name Dosage & Administration 
Darifenacin hydrombromide Enablex 7.5 to 15 mg daily 
Fesoterodine Toviaz 4 mg daily, can be increased to 8 mg daily 
Oxybutynin extended release Ditropan XL 5 mg daily, titrate up to 20-30 mg daily 
Oxybutynin gel Gelnique Topical 10% gel applied as 1 g daily to 
thigh, abdomen, upper arm or shoulder 
Oxybutynin immediate 
release 
Ditropan 2.5 mg 2-3 times daily, followed by 
titration as needed u to 20 mg/d in 
divided doses 
Oxybutynin transdermal Oxytrol Applied to abdomen, hip or buttock and 
changed twice per week (equivalent to 3.9 
mg/d) 
Solifenacin succinate Vesicare 5-10 mg daily 
Tolterodine tartrate extended 
release 
Detrol LA 2-4 mg daily 
Tolterodine tartrate 
immediate release  
Detrol 1-2 mg twice daily 
Trospium chloride extended 
release 
Sanctura 60 mg daily 
Trospium chloride immediate 
release 
Sanctura 20 mg twice daily 
Table 1. Commonly prescribed anticholinergic drugs for treatment of OAB 
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5.2.2 Antidepressants 
5.2.2.1 Duloxetine 
Duloxetine is a serotonin noradrenaline re-uptake inhibitor that is approved by the Food 
and Drug Administration (FDA) for depression, but not for urinary incontinence. The 
mechanism of action is to significantly increase sphincteric muscle activity during the 
filling/storage phase of micturition. Although not approved for use in patients with OAB 
symptoms alone, it may have some efficacy. Steers et al (Steers et al., 2007) randomized 306 
women to placebo or duloxetine over 12 weeks. Duloxetine showed significant benefit in 24-
hour urinary frequency and incontinence episodes. It also improved condition-specific 
quality of life measures. However, no significant increase was observed in mean voided 
volume, suggesting that the benefits were mediated through an effect at the urethral 
rhabdosphincter, rather than any direct effect on detrusor contractility. Thus, duloxetine 
may be considered as an option for patients who cannot tolerate antimuscarinic drugs. 
However, duloxetine’s primary efficacy is in the treatment of stress urinary incontinence. 
5.2.2.2 Imipramine 
Imipramine, an antidepressant, is the only drug in this category that has been widely used 
to treat the symptoms of OAB. It has multiple pharmacological effects, including systemic 
antimuscarinic actions and blockade of the reuptake of serotonin and noradrenaline, but its 
mode of action in the treatment of OAB is not clear. (Hunsballe & Djurhuus, 2001) 
Imipramine has shown a favorable therapeutic effect in the treatment of nocturnal enuresis 
in children with a success rate of 10–70% in controlled trials. (Glazener et al., 2003; 
Hunsballe & Djurhuus, 2001) However, there are no good quality randomized trials that 
prove the efficacy of imipramine in the treatment of OAB. 
5.2.3 Intravesical botulinum toxin 
Botulinum toxin is a neurotoxin that inhibits the release of acetylcholine from presynaptic 
cholinergic nerve endings. This inhibition results in a localized reversible chemical 
denervation, with decreased detrusor contractility. Although it is currently not FDA-
approved for the treatment of OAB, it shows promise as an addition to the treatment 
arsenal. The most likely place for its use is for patients who fail oral therapies. Current data 
primarily address only patients with refractory detrusor overactivity. In the most recent 
Cochrane review, randomized trials of intravesical botulinum versus placebo reported 
results favoring botulinum toxin. (Duthie et al., 2007) The authors noted that there was 
significant improvement in incontinence episodes, bladder capacity, maximum detrusor 
pressure and quality of life. They concluded “Botulinum toxin injections into the bladder 
appeared to give few side effects or complications, but there were no long-term follow-up 
studies, and there could be rare side effects that have not been discovered yet.” (Duthie et 
al., 2007)  
As stated above, many questions remain regarding its use, including the optimal dose and 
site of injection, the appropriate population, and long-term safety. To address this issue, 
Schurch et al (Schurch et al., 2007) randomized 59 patients with neurogenic detrusor 
overactivity to intravesical botulinum A (200 or 300 U) or placebo. These investigators noted 
significant improvements when compared to placebo using the Incontinence Quality of Life 
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Questionnaire. They did not discover clear differences between the two doses. Intravesical 
botulinum toxin has a variable duration of action, with loss of efficacy typically seen within 
one year. (Reitz et al., 2007) Based upon this limited data, it appears that there may be a role 
for the use of intravesical botulinum for patients with OAB, especially when other therapies 
fail. Finally, one of the bothersome adverse effects is urinary retention which can last up to 
three months after one injection. This, the clinician must have considerable knowledge and 
skill in the judicious use of botulinum toxin.  
In a recent literature review (Anger et al, 2010) the authors systematically reviewed the 
efficacy and safety of botulinum toxin in the management of overactive bladder. Based upon 
this review of three small randomized placebo controlled trials they found that patients 
treated with botulinum toxin-A had 3.88 fewer incontinence episodes per day (95% CI -6.15, 
-1.62). Patients also noted significant improvements in quality of life compared with 
placebo. In addition they found a 9-fold increased odds of increased post-void residual after 
botulinum toxin-A compared with placebo (8.55; 95% CI 3.22, 22.71). They concluded that 
“intravesical injection of botulinum toxin resulted in improvement in medication refractory 
overactive bladder symptoms”.  
5.2.4 Combination therapies 
Since most patients do not achieve complete continence with behavioral therapy or 
anticholinergic therapies alone, many clinicians combine these two in the treatment of OAB. 
A combination of anticholinergic agents and behavioral interventions have been shown to 
be safe and effective in many studies. (Fantl et al., 1996; Gormley, 2002; Milne & Moore, 
2006) Side affect profiles of most of the drugs used for OAB make long term adherence to 
therapy difficult.  
In a large study, Mattiasson et al (Mattiasson et al., 2003) showed additional benefit from 
bladder retraining when compared with tolterodine alone. Additionally, 76% of the patients 
on tolterodine and behavioral therapy noted improvement in their bladder symptoms 
compared to baseline as compared with 71% in the tolterodine group (Mattiasson et al., 
2003)  
Combination therapy has been shown to be associated with significantly fewer incontinent 
episodes, an improved quality of life, and greater treatment satisfaction when compared to 
non-pharmacologic intervention alone or drug treatment alone. (Wyman et al., 1998) 
However, the authors found that the effects of each of the interventions were similar 3 
months after treatment. They concluded that the nature of the treatment may not be as 
important as having a structured intervention program that includes education, counseling, 
and frequent monitoring of the treatment. (Wyman et al., 1998) 
Finally, Chancellor et al ( Chancellor et al., 2008), in a more recent trial, compared the 
benefits of anticholinergic therapy alone against a combination of anticholinergic and 
behavioral therapy in 395 patients in a randomized controlled trial of flexible dose 
darifenacin (7.5 mg/day increased to 15 mg/day if required), with or without additional 
advice about dietary modification, timed voiding/bladder retraining, and pelvic floor 
training. No significant differences were observed between groups in OAB symptoms. 
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5.3 Neuromodulation 
Neuromodulation can be utilized to increase pelvic muscle contraction and decrease 
detrusor contractions. The use of neuromodulation is assumes that OAB results from an 
imbalance of inhibitory and excitatory control systems of the detrusor that leads to the 
symptoms of OAB during the filling phase. (Fall and Lindstrom ,1991) Neuromodulation is 
gaining popularity because it bridges the gap between conservative treatments and highly 
invasive options. Currently, the methods used include sacral nerve modulation (SNM) via 
surgically implanted electrodes and other newer methods that deliver percutaneous 
stimulation of the peripheral tibial nerve.  
The exact mechanism of action for neuromodulation is not well understood. However, 
many theories have been proposed as follows. (Al-Shaiji et al, 2011) 
 Sensory input through the pudendal nerve has been shown to inhibit detrusor activity. 
Pudendal nerve stimulation and enhancement of external sphincter tone may serve to 
control bladder overactivity and facilitate urine storage. (Vodusek et al, 1986) 
 The bladder responds to neural stimulation initially with rapid contraction. This is then 
followed by slow, longer-lasting relaxation. With recurrent, repetitive electrical 
stimulation, there is a downregulation of the bladder’s response, thus reducing the 
detrusor muscle overactivity. (Appell & Boone, 2007) 
 Stimulation of afferent sacral nerves in the pelvis or lower extremities has been shown 
to increase the inhibitory stimuli to the efferent pelvic nerve thus reducing detrusor 
contractility. (Fall & Lindstrom, 1991) 
 Neuromodulation affects the “neuroaxis” at various levels and restores the balance 
between excitatory and inhibitory regulation at various locations within the peripheral 
and central nervous system. (Van Der Pal, 2006) 
5.3.1 Noninvasive electrical stimulation 
There are several devices on the market to provide noninvasive electrical stimulation to the 
pelvic floor. The removable device is placed in the. Its mechanism of action in the treatment 
of OAB is thought to be secondary to reflex inhibition of the detrusor muscle by stimulation 
of the pudendal nerve. There is some evidence that this therapy has some efficacy in the 
treatment of OAB. (Berghmans et al., 2000; Goode et al., 2003) 
5.3.2 Sacral neuromodulation (SNM) 
SNM uses mild electrical pulses to stimulate the sacral nerves that innervate the pelvic floor 
and lower urinary tract. InterStimTM therapy was developed by Medtronic (Minneapolis, 
Minn, USA) for use in humans. This technology utilizes an implanted unilateral lead 
stimulating the S3 nerve root. This electrode is attached to a small pacemaker placed within 
a subdermal pocket in the buttock region. It is FDA approved for refractory urge 
incontinence, refractory urgency frequency, and idiopathic nonobstructive urinary 
retention. “Off-label uses of the technology include for treatment of interstitial cystitis and 
pelvic pain syndrome. (Al-Shaiji et al, 2011) 
Implantation of the device usually proceeds in 2 steps: a test phase and implantation or lead 
removal based on test response. The initial test phase can be performed in the office or 
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operating room allowing for placement of the lead with a test period of 1 to 2 weeks; full 
implantation can be performed under local or general anesthesia. Response is objectively 
evaluated by pre- and postvoiding diaries assessing various urinary parameters. 
The test phase of the procedure consists of implantation of tined quadripolar leads, under 
intravenous (IV) sedation, local anaesthesia, or general anaesthesia. Under fluoroscopy with 
a C-arm the right or left S3 foramen is identified and the permanent tined lead is passed 
through the foramen needle. The lead is then tested for a response. Correct placement in the 
S3 foramina includes bellows contraction of the pelvic floor and plantar flexion of the great 
toe. Once the appropriate side and position is selected, the lead is connected to an external 
pulse generator and taped to the skin surface. A 7- to 14-day home test period is used to 
determine which patients meet criteria to have the IPG implanted. Patients who respond 
favorably and demonstrate a 50% symptom improvement from baseline have the permanent 
generator implanted. (Al-Shaiji et al, 2011) 
The most common adverse events include lead migration, implant site pain, bowel 
dysfunction, and infection. Infection usually resolves with antibiotics and the lead adverse 
events can usually be corrected by reprogramming, reinforcing the lead, or inserting a new 
lead contralaterally. 
There is now convincing evidence for the success of SNM for refractory OAB. Several 
studies including RCTs and long-term observational studies reported fair clinical response 
between 64 and 88% of all patients (Leong et al, 2010).  
5.3.3 Percutaneous stimulation of the tibial nerve 
In addition, percutaneous stimulation of the tibial nerve (PTNS) has shown promise in the 
treatment of patients with refractory urge incontinence. PTNS is a minimally invasive, 
office-based procedure that involves percutaneous placement of a 34-gauge (ga) needle over 
the medial malleolus of the ankle to provide stimulation of the posterior tibial nerve. The 
procedure is repeated in 30-minute treatment sessions over a period of 12 weeks. PTNS in 
patients with OAB has been shown to significantly reduce in symptoms and improvement 
in health-related quality of life. (Yoong et al, 2010) However, one multicenter randomized 
trial of 100 patients with OAB symptoms did not show a reduced rate of urinary frequency 
when PTNS was compared to tolterodine extended release, 4mg daily. (Peters, 2009) 
5.4 Surgery 
In general most patients with OAB symptoms can be treated with medical and behavioral 
therapies. Generally, augmentation cystoplasty is only considered when patients have small 
volume bladders and are debilitated by their symptoms. 
5.4.1 Augmentation cystoplasty 
Augmentation cystoplasty (AC) is a surgery where a portion of the bowel is removed and 
patched to the bisected bladder. This procedure increases bladder capacity and decreases 
bladder pressure caused by unstable detrusor contractions. Considered a procedure of last 
resort, the risks of the surgery include recurrent UTI’s, renal or bladder infections, metabolic 
changes and mucus production. (Khastgir et al., 2003) reviewed outcomes associated with 
www.intechopen.com
 
Urinary Incontinence 180 
augmentation cystoplasty. This group emphasized clinical outcomes (e.g. maximum 
detrusor pressure and bladder volume capacity) and patient symptoms (e.g. incontinence 
episodes and number of pads). Other outcomes included a questionnaire that measured 
quality of life, and the evaluation of complications from the surgery.  
Using a definition of success as a > 50% reduction in symptoms, one group found a 97% 
success rate for AC. (Blaivas et al., 2005) 
5.5 Future therapies 
5.5.1 Beta adrenoreceptor agonists 
The human detrusor muscle contains B2 and B3-adrenoceptors. Both receptors are thought to 
be involved in detrusor relaxation. Currently, there are a number of [beta] 3-adrenoceptor 
selective agonists being evaluated as potential treatment for OAB, including YM178 
(mirabegron). Chapple et al (Chapple et al., 2008) conducted a clinical trial with mirabegron 
versus tolterodine and placebo in patients with OAB. Patients in the treatment arm had a 
statistically significant reduction in mean micturition frequency when compared to placebo. 
In addition, mirabegron was superior to placebo in regard to mean volume voided per 
micturition, mean number of incontinence episodes, nocturia episodes, urgency 
incontinence episodes, and urgency episodes per 24 hours. The drug was well tolerated, and 
the most commonly reported adverse effects were headache and gastrointestinal adverse 
effects. Further randomized trials will be needed to prove efficacy. 
5.5.2 Centrally acting drugs 
5.5.2.1 Tramadol 
Many parts of the brain are activated during storage and voiding and there is increasing 
interest in centrally acting drugs which modulate the micturition reflex. (Andersson & 
Pehrson, 2003) Tramadol is an analgesic that is a weak μ-receptor agonist; however, it is 
metabolized to several different compounds, which inhibit serotonin (5-HT) and 
noradrenaline reuptake. (Grond & Sablotzki, 2004;Safarinejad & Hosseini, 2006) Both μ-
receptor agonist and amine reuptake inhibition are useful in the treatment of OAB. In a 
double-blind, placebo-controlled, randomized study, 76 patients were given 100 mg 
tramadol sustained release every 12 hours for 12 weeks. Tramadol significantly reduced the 
number of incontinence periods by 50% per 24 hours. The authors concluded that tramadol 
provided beneficial clinical and urodynamic effects. 
5.5.2.2 Tachykinins 
Tachykinins such as substance P, neurokinin A (NKA), and neurokinin B (NKB) may play a 
role in OAB. Substance P has a specific receptor (NK1) that is expressed in the dorsal horn of 
the spinal cord and may play an important role in detrusor overactivity. (Grond & Sablotzki, 
2004; Safarinejad & Hosseini, 2006)  
Aprepitant, an NK1 receptor antagonist, has been shown to significantly improve symptoms 
of OAB in postmenopausal women with a history of urgency incontinence or mixed 
incontinence in a small pilot. (Green et al., 2006) Aprepitant significantly decreased the 
average daily number of micturitions (−1.3 ± 1.9) compared with placebo (−0.4 ± 1.7). The 
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average daily number of urgency episodes was significantly reduced, as were the average 
daily number of urgency incontinence and total urinary incontinence episodes. The authors 
concluded that NK1 receptor antagonism holds promise as a potential treatment approach 
for OAB. 
6. Summary 
Overactive bladder (OAB) is a common medical condition, yet often undetected and 
undertreated despite the substantial impact on a woman's quality of life. The etiology of 
OAB is unclear, but several mechanisms may interplay and interconnected in contributing 
to the multi-symptom condition. Despite symptoms that often interfere with work, daily 
life, intimacy, and also cause embarrassment and diminished self-esteem, less than half of 
sufferers seek treatment from a licensed provider.  
A working clinical diagnosis of OAB can usually be made simply by utilizing proper 
urinary questionnaires, urinary diaries or a thorough medical history and physical 
examination. Confirmation of diagnosis is most often achieved via a post-void residual, 
simply cystometry or multichannel urodynamic testing. 
The primary goal of treatment of OAB is simply a reduction in urinary incontinence 
episodes. First-line therapy for OAB should include conservative options such as timed 
voiding and alterations in types and amount of fluid intake. Counseling patients on dietary 
and lifestyle modification will often improve their acute symptoms and decrease the 
number of voiding episodes per day. Other non surgical first line options include pelvic 
floor muscle training and/or biofeedback, both of which center around exercises designed 
to improve the function of the pelvic floor muscles. The primary limitations of behavioral 
therapy is the required long term patient commitment required for effectiveness.  
Antimuscarinic (anticholinergic) drugs are the cornerstone of pharmacological treatment of 
OAB and provide a favorable efficacy/tolerability/safety profile. These result in decreased 
bladder contractions and thus reduced the symptoms of OAB. For patients who are not 
candidates for antimuscarinic (anticholinergic) therapy or have failed previous trials of 
other medical therapy, noninvasive electrical stimulation to the pelvic floor via 
neuromodulation may increase pelvic muscle contractions and decrease detrusor 
contractions . More aggressive nerve modulation and stimulation therapies include, sacral 
nerve stimulation or peripheral nerve stimulation , which can be considered in patients with 
refractory urge incontinence. Lastly, surgical options, including augmentation cystoplasty 
and detrusor myectomy have been developed for those in which all other treatment 
alternatives have been exhausted.  
Lastly, there are promising new receptor-specific medical alternatives emerging and future 
studies will determine their place in the therapeutic arsenal. 
Despite the prevalence of OAB, and the patients’ lack of willingness to report their life 
altering symptoms, screening for OAB should be part of every woman’s annual well woman 
visit. Health care providers need not shy away from urinary incontinence questionnaires, as 
straightforward diagnosis and OAB treatments are available. Although the primary 
treatment goal of OAB is the reduction in urinary incontinence episodes, to the patient, the 
most important measure is quality of life. 
www.intechopen.com
 
Urinary Incontinence 182 
7. References 
Abrams P, Cardozo L, Fall M, et al; Standardisation Sub-committee of the International 
Continence Society. The standardisation of terminology of lower urinary tract 
function: report from the Standardisation Sub-committee of the International 
Continence Society. Neurourol Urodyn 2002;21:167–178.  
Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 
2007;100:987–1006.  
Al-Shaiji TF, Banakhar M, Hassouna MM. Pelvic Electrical Neuromodulation for the 
Treatment of Overactive Bladder Symptoms. Advances in Urology. Volume 2011, 
Article ID 757454, 7 pages. doi:10.1155/2011/757454 
Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release 
oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study 
Group. J Urol 1999; 161:1809.  
Anderson KE. Potential benefits of Muscarinic M3 receptor selectivity,” European Urology 
Supplements, vol. 1, no. 4, pp. 23–28, 2002. 
Andersson KE. Bladder activation: afferent mechanisms. Urology 2002; 59:43. 
Andersson KE, Pehrson R. CNS involvement in overactive bladder: pathophysiology and 
opportunities for pharmacological intervention. Drugs 2003;63:2595–2611. 
Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and 
future treatments of urinary incontinence. Pharmacol Rev 2004;56:581–631.  
Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn 2007;26(6 
suppl):934–947  
Appell R, Boone TB. Surgical management of overactive bladder, Current Bladder 
Dysfunction Reports, vol. 2, pp. 37–45, 2007. 
Arya LA, Myers DL, and Jackson ND. Dietary caffeine intake and the risk for detrusor 
instability: a case-control study. Obstetrics and Gynecology, vol. 96, no. 1, pp. 85–
89, 2000.  
Anger JT, Weinberg A, Suttorp MJ, Litwin, MS, Shekelle PG. Outcomes of intravesical 
botulinum toxin for idiopathic overactive bladder symptoms: a systematic review. 
Journal of Urology. 183(6):2258-2264, June 2010. 
Araki, I., et al., Lower urinary tract symptoms in men and women without underlying 
disease causing micturition disorder: a cross-sectional study assessing the natural 
history of bladder function. J Urol, 2003. 170(5): p. 1901-4. 
Azadzoi, K.M., et al., Canine bladder blood flow and oxygenation: changes induced by 
filling, contraction and outlet obstruction. J Urol, 1996. 155(4): p. 1459-65. 
Basra R, Artibani W, Cardozo L, et al. Design and validation of a new screening instrument 
for lower urinary tract dysfunction: the bladder control self-assessment 
questionnaire (B-SAQ). Eur Urol 2007;52:230–237.  
Berghmans LC, Hendriks HJ, De Bie RA, et al. Conservative treatment of urge urinary 
incontinence in women: a systematic review of randomized clinical trials. BJU Int 
2000; 85:254.  
Blakeman PJ, Hilton P,Bulmer JN. Oestrogen and progesterone receptor expression in the 
female lower urinary tract, with reference to oestrogen status. BJU Int, 2000.86(1): 
p. 32-8. 
Bo K, Berghmans LCM. Nonpharmacologic treatments for overactive bladder—pelvic floor 
exercises. Urology, vol. 55, no. 5, supplement 1, pp. 7–11, 2000.  
www.intechopen.com
 
Diagnosis and Treatment of Overactive Bladder 183 
Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder 
syndrome and similar diseases in women: a systematic review. J Urol 2007; 177:450.  
Blaivas JG, Weiss JP, Desai P, Flisser AJ, Stember DS, Stahl PJ: Longterm followup of 
augmentation enterocystoplasty and continent diversion in patients with benign 
disease. The Journal of urology 2005, 173(5):1631-1634. 
Blaivas JG, Panagopoulos G, Weiss JP, et al. Validation of the overactive bladder symptom 
score. J Urol 2007;178:543–547; discussion 547.  
Bros E, ComarrAE. Physiology of Micturition, Its Neurological Disorders and Sequelae. 
1971, Baltimore: University Park Press. 
Brubaker L, Fanning K, Goldberg EL, et al. Predictors of discontinuing overactive bladder 
medications. BJU Int 2010;105:1283–1290.  
Burgio KL, Whitehead WE, Engel BT. Urinary incontinence in the elderly. Bladder-sphincter 
biofeedback and toileting skills training. Ann Intern Med 1985;103:507–515.  
Burgio KL. Influence of behavior modification on overactive bladder. Urology 2002;60(5 
suppl 1):72–76; discussion 77. 
Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment 
success for overactive bladder with urinary urge incontinence refractory to oral 
antimuscarinics: a review of published evidence. BMC Urology 2009, 9:18. 
Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of 
the once daily antimuscarinic agent solifenacin succinate in patients with 
overactive bladder. Journal of Urology, vol. 172, no. 5, part 1, pp. 1919–1924, 2004. 
Cardozo, L., et al., A systematic review of the effects of estrogens for symptoms suggestive 
of overactive bladder. Acta Obstet Gynecol Scand, 2004. 83(10): p. 892-7. 
Cardozo L, Hessdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other 
symptoms of overactive bladder: results from a randomized, double-blind, 
placebocontrolled, rising-dose trial. BJU International, vol. 102, no. 9, pp. 1120–
1127, 2008. 
Chapple CR, Martinez-Garcia R, Selvaggi L, et al; for the STAR study group. A comparison 
of the efficacy and tolerability of solifenacin succinate and extended release 
tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur 
Urol 2005;48:464–470. 
Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all 
symptoms of overactive bladder syndrome,” International Journal of Clinical 
Practice, vol. 60, no. 8, pp. 959–966, 2006.  
Chapple CR, Fianu-Jonsson A, Indig M, et al; STAR study group. Treatment outcomes in the 
STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 
2007;52:1195–1203.  
Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (Blossom) shows 
novel β3 adrenoceptor agonist YM178 is effective and well tolerated in the 
treatment of symptoms of overactive bladder. Eur Urol Suppl 2008.  
Chancellor MB, Kianifard F, Beamer E, et al. A comparison of the efficacy of darifenacin 
alone vs. darifenacin plus a Behavioural Modification Programme upon the 
symptoms of overactive bladder. Int J Clin Pract 2008;62:606–613.  
Choo MS, Doo CK, Lee KS. Satisfaction with tolterodine: assessing symptom-specific 
patient-reported goal achievement in the treatment of overactive bladder in female 
patients (STARGATE study),” International Journal of Clinical Practice, vol. 62, no. 
2, pp. 191–196, 2008.  
www.intechopen.com
 
Urinary Incontinence 184 
Colli E, Digesu GA, Olivieri L. Overactive bladder treatments in early phase clinical trials. 
Expert Opin Investig Drugs 2007;16:999–1007.  
Coyne KS, Zyczynski T, Margolis MK, et al. Validation of an overactive bladder awareness 
tool for use in primary care settings. Adv Ther 2005;22:381–394. 
Coyne KS, Matza LS, Thompson CL. The responsiveness of the overactive bladder 
questionnaire (OAB-Q). Qual Life Res 2005;14:849–855.  
Davila GW, Daugherty CA, Sanders SW, Transdermal Oxybutynin Study Group. A short-
term, multicenter, randomized double-blind dose titration study of the efficacy and 
anticholinergic side effects of transdermal compared to immediate release oral 
oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166:140.  
de Nunzio, C., et al., The evolution of detrusor overactivity after watchful waiting, medical 
therapy and surgery in patients with bladder outlet obstruction. J Urol, 2003. 
169(2): p. 535-9. 
de Groat, W.C., A.M. Booth, and N. Yoshimura, Neurophysiology of micturition and its 
modeification in animal models of human disease, in The Autonomic Nervous 
System:Nervous Control of the Urogenital System, C.A. Maggi, Editor. 1993, 
Harwood Academic Publishers: London. p.27-290. 
de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol 
Toxicol 2001;41:691–721.  
de Groat WC. The urothelium in overactive bladder: passive bystander or active 
participant? Urology 2004;64(6 suppl 1):7–11. 
Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal 
oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 
168:580. 
Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for 
overactive bladder syndrome: results from a placebo-controlled interventional 
study. Urology 2008; 71:449.  
DuBeau CE. (2011). Treatment of urinary incontinence, In: UpToDate, accessed 8/18/2011, 
Available from: http://www.uptodate.com/contents/treatment-of-urinary-
incontinence?source=search_result&selectedTitle=1%7E81#H3 
Duthie J, Wilson DI, Herbison GP, et al. Botulinum toxin injections for adults with 
overactive bladder syndrome. Cochrane Database Syst Rev 2007;3:CD005493. 
Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. II. 
Aging detrusor: normal versus impaired contractility. J Urol, 1993. 150(5 Pt 2): 
p.1657-67. 
Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. 
Detrusor overactivity. J Urol, 1993. 150(5 Pt 2): p. 1668-80. 
Elbadawi A, Yalla SV, Resnick NM.. Structural basis of geriatric voiding dysfunction. IV. 
Bladder outlet obstruction. J Urol, 1993. 150(5 Pt 2): p. 1681-95. 
Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of 
atrophic vaginitis: a doubleblind placebo controlled study. Eur J Obstet Gynecol 
Reprod Biol, 1992. 44(2): p. 137-44. 
Fall, M., B.L. Ohlsson, and C.A. Carlsson, The neurogenic overactive bladder. Classification 
based on urodynamics. Br J Urol, 1989. 64(4): p. 368-73. 
Fall M, Lindstrom S, Electrical stimulation: a physiologic approach to the treatment of urinary 
incontinence, Urologic Clinics of North America, vol. 18, no. 2, pp. 393–407, 1991. 
www.intechopen.com
 
Diagnosis and Treatment of Overactive Bladder 185 
Fall, M., G. Geirsson, and S. Lindstrom, Toward a new classification of overactive bladders. 
Neurourol Urodyn, 1995. 14(6): p. 635-46. 
Fantl JA, Newman DK, Colling J, et al. Urinary Incontinence in Adults: Acute and Chronic 
Management, Clinical 
Practice Guideline no. 2, Agency for Health Care Policy and Research, Rockville,Md, USA, 
1996, AHCPR publication no. 96-0682. 
Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial 
cells by hydrostatic pressure changes—a possible sensory mechanism? J Physiol, 
1997. 505 ( Pt 2): p. 503-11. 
Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older 
patient: pooled analysis of three phase III studies of darifenacin, an M3 selective 
receptor antagonist,” European Urology, vol. 48, no. 3, pp. 471–477, 2005. 
Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 
2008; 9:453. 
Glazener CM, Evans JH, Peto RE. Tricyclic and related drugs for nocturnal enuresis in 
children. Cochrane Database Syst Rev 2003;3:CD002117. 
Goode PS, Burgio KL, Locher JL, et al. Effect of behavioral training with or without pelvic 
floor electrical stimulation on stress incontinence in women: a randomized 
controlled trial. JAMA 2003; 290:345. 
Gormley EA. Biofeedback and behavioral therapy for the management of female urinary 
incontinence,” Urologic 
Clinics of North America, vol. 29, no. 3, pp. 551–557, 2002. 
Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in 
postmenopausal women with overactive bladder with urge urinary incontinence. J 
Urol 2006;176:2535–2540. 
Greenland JE,Brading AF. The effect of bladder outflow obstruction on detrusor blood flow 
changes during the voiding cycle in conscious pigs. J Urol, 2001. 165(1): p.245-8 
Griffiths AN, Makam A, Edwards GJ. Should we actively screen for urinary and anal 
incontinence in the general gynaecology outpatients setting?—a prospective 
observational study. J Obstet Gynaecol 2006;26:442–444.   
Griffiths D, Tadic SD, Schaefer W, Resnick NM. Cerebral control of the bladder in normal 
and urge-incontinent women. Neuroimage 2007; 37:1.  
Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879–
923. 
Haab F, Corcos J, Siami P, et al. Long-termtreatment with darifenacin for overactive bladder: 
results of a 2-year, open label extension study,” BJU International, vol. 98, no. 5, pp. 
1025–1032, 2006. 
Harrison, S.C., et al., Bladder instability and denervation in patients with bladder outflow 
obstruction. Br J Urol, 1987. 60(6): p. 519-22. 
Harris SS, Link CL, Tennstedt SL, et al. Care seeking and treatment for urinary incontinence 
in a diverse population. J Urol 2007;177:680–684. 
Hay-Smith J, Herbison P, Ellis G, et al. Which anticholinergic drug for overactive bladder 
symptoms in adults. Cochrane Database Syst Rev 2005;3:CD005429. 
Hay-Smith, J, Berghmans, BK, et al. Adult conservative management. In: Abrams, P, 
Cardozo, L, Khoury, S, Wein, A. Paris: Editions 21, for Health Publications Ltd, 
2009; p.1025. 
www.intechopen.com
 
Urinary Incontinence 186 
Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in 
patients aged 65 years and older: analysis of results from a 2-year, open-label 
extension study. Current Medical Research and Opinion, vol.23, no. 11, pp. 2697–
2704, 2007. 
Homma Y. The clinical significance of the urodynamic investigation in incontinence. BJU Int 
2002;90:489–497.  
Hosker G, Rosier P, Gajewski J, Sand P, Szabo L, Capewell A. Dynamic testing. In:Abrams P, 
Cardozo L, Khoury S, Wein A. Incontinence. Health Publication Ltd 2009 Paris 
France. 
Hughes KM, Lang JCT, Lazare R, et al. Measurement of oxybutynin and its N-desethyl 
metabolite in plasma, and its application to pharmacokinetic studies in young, 
elderly and frail elderly volunteers,” Xenobiotica, vol. 22, no. 7, pp. 859–869, 1992. 
Hunsballe JM, Djurhuus JC. Clinical options for imipramine in the management of urinary 
incontinence. Urol Res 2001;29:118–125. 
International Continence Society. Available at www.ics.org. Accessed 10/14/2011. 
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, 
overactive bladder, and other lower urinary tract symptoms in five countries: 
results of the EPIC study. Eur Urol 2006;50:1306–1315.  
Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, 
social interactions and emotional well-being in six European countries. BJU Int 
2006;97:96–100. 
Ishizuka O, Igawa Y, Lecci A, et al. Role of intrathecal tachykinins for micturition in 
unanaesthetized rats with and without bladder outlet obstruction. Br J Pharmacol 
1994;113:111–116. 
Janknegt RA, Hassouna MM, Siegel SW, et al. Long-term effectiveness of sacral nerve 
stimulation for refractory urge incontinence. Eur Urol 2001;39:101–106. 
Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin 
and oxybutynin ER on memory in older subjects. European Urology, vol. 50, no. 2, 
pp. 317–326, 2006. 
Khastgir J, Hamid R, Arya M, Shah N, Shah PJ: Surgical and patient reported outcomes of 
'clam' augmentation ileocystoplasty in spinal cord injured patients. Eur Urol 2003, 
43(3):263-269. 
Koelbl H, Nitti V, Baessler K, Salvatore S, Sultan A, Yamaguchi O. Pathophysiology of 
Urinary Incontinence, 
Faecal Incontinence and Pelvic Organ Prolapse. In:Abrams P, Cardozo L, Khoury S, Wein A. 
Incontinence Health Publication Ltd 2009 Paris France. 
Leong RK, De Wachter SGG, Van Kerrebroeck,PEV. Current information on sacral 
neuromodulation and 
botulinumtoxin treatment for refractory idiopathic overactive bladder syndrome: a review, 
Urologia Internationalis, vol. 84, no. 3, pp. 245–253, 2010. 
Mansfiel, KJ et al., Muscarinic receptor subtypes in human bladder detrusor and mucosa, 
studied by radioligand 
binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol, 2005. 
144(8): p. 1089-99. 
Mardon RE, Halim S, Pawlson LG, et al. Management of urinary incontinence in Medicare 
managed care beneficiaries: results from the 2004 Medicare Health Outcomes 
Survey. Arch Intern Med 2006;166:1128–1133.  
www.intechopen.com
 
Diagnosis and Treatment of Overactive Bladder 187 
Mattiasson A, Blaakaer J, Høye K, et al. Simplified bladder training augments the 
effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 
2003;91:54–60.  
McGrother CW, Donaldson MM, Hayward T, et al; Leicestershire MRC Incontinence Study 
Team. Urinary storage symptoms and comorbidities: a prospective population 
cohort study in middle-aged and older women. Age Ageing 2006;35:16–24.  
Mills IW et al., Studies of the pathophysiology of idiopathic detrusor instability: the 
physiological properties of the detrusor smooth muscle and its pattern of 
innervation. J Urol, 2000. 163(2): p. 646-51. 
Milne JL and Moore KN. Factors impacting self-care for urinary incontinence,” Urologic 
Nursing, vol. 26, no. 1, pp. 41–51, 2006. 
Milne JL. Behavioral therapies for overactive bladder: making sense of the evidence. Journal 
of Wound, Ostomy and Continence Nursing, vol. 35, no. 1, pp. 93–101, 2008. 
Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive 
bladder and how are they managed? A population-based prevalence study. BJU Int 
2001;87:760–766. 
Nilvebrant L, Sparf B. Dicyclomine, benzhexol, and oxybutynine distinguish between 
subclasses of muscarinic binding sites. European Journal of Pharmacology, vol. 123, 
no. 1, pp. 133–143, 1986. 
Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary 
urgency severity in overactive bladder for use in clinical trials. J Urol 2005;174:604–
607. 
Nygaard IE, Kreder KJ, Lepic MM, Fountain KA, Rhomberg AT. Efficacy of pelvic floor muscle 
exercises in women with stress, urge, and mixed urinary incontinence. American 
Journal of Obstetrics and Gynecology, vol. 174, no. 1, part 1, pp. 120–125, 1996. 
Ouslander JG, Ai-Samarrai N, Schnelle JF. Prompted voiding for nighttime incontinence in 
nursing homes: is it effective? J Am Geriatr Soc 2001;49:706–709. 
Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial 
nerve stimulation versus extended-release tolterodine: results from the 
overactive bladder innovative therapy trial. J Urol 2009;182:1055–1061. Reitz A, 
Denys P, Fermanian C, et al. Do repeat intradetrusor botulinum toxin type A 
injections yield valuable results? Clinical and urodynamic results after five 
injections in patients with neurogenic detrusor overactivity. Eur Urol 
2007;52:1729–1735.  
Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of idiopathic 
detrusor overactivity: a double-blind, placebo-controlled, randomized study. Br J 
Clin Pharmacol 2006;61:456–463.  
Schafer W et al., Good urodynamic practices: uroflowmetry, filling cystometry, and 
pressure-flow studies. Neurourol Urodyn, 2002. 21(3): p. 261-74. 
Schurch B, Denys P, Kozma CM, et al. Botulinum toxin A improves the quality of life of 
patients with neurogenic urinary incontinence. Eur Urol 2007;52:850–858. 
Shaw HA, Burrows LJ. Etilogy and treatment of overactive bladder in women. South Med J. 
2011 Jan;104(1):34-9. Review. 
Staskin D, Sand P, Zinner N, Dmochowski R. Once daily trospium chloride is effective and 
well tolerated for the treatment of overactive bladder: results from a multicenter 
phase III trial. Journal of Urology, vol. 178, no. 3, pp. 978–984, 2007. 
www.intechopen.com
 
Urinary Incontinence 188 
Steers WD, Herschorn S, Kreder KJ, et al; Duloxetine OAB Study Group. Duloxetine 
compared with placebo for treating women with symptoms of overactive bladder. 
BJU Int 2007;100:337–345. 
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive 
bladder in the United States. World J Urol 2003;20:327–336. 
Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight 
and obese women. N Engl J Med 2009; 360:481. 
Swithinbank L, Hashim H, and Abrams P, “The effect of fluid intake on urinary symptoms 
in women,” Journal of Urology, vol. 174, no. 1, pp. 187–189, 2005.  
Van Der Pal F, Heesakkers JPFA, Bemelmans BLH. Current opinion on the working 
mechanisms of neuromodulation in the treatment of lower urinary tract 
dysfunction, Current Opinion in Urology, vol. 16, no. 4, pp. 261–267, 2006. 
van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral 
neuromodulation therapy for urinary voiding dysfunction: outcomes of a 
prospective, worldwide clinical study. J Urol 2007;178:2029–2034.  
Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release 
oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 
2000; 95:718.  
Vodusek, DB, Light JK, Libby JM. Detrusor inhibition induced by stimulation of pudendal 
nerve afferents. Neurourology and Urodynamics, vol. 5, no. 4, pp. 381–389, 1986. 
Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU 
Int 2007;99:502–509.  
Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in 
adults. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: 
CD001308. DOI: 10.1002/14651858.CD001308.pub2  
Wein AJ. Pathophysiology and categorization of voiding dysfunction, in Walsh P, Retik A, 
Vaughan ED Jr, et al (eds): Campbell's Urology. Philadelphia, Saunders, 2002, ed 8, 
pp 887.  
Wilson PD, Berghmans B, Hagen S, et al. Adult conservative management, in Abrams P, 
Cardozo L, Khoury S, et al (eds): Incontinence Management. Paris, Health 
Publications, 2005, pp 855–894. 
Wyman JF, Fantl JA, McClish DK, Bump RC. Comparative efficacy of behavioral 
interventions in themanagement of female urinary incontinence. American Journal 
of Obstetrics and Gynecology, vol. 179, no. 4, pp. 999–1007, 1998. 
Yoong W, Ridout AE, Damodaram M, Dadswell R. Neuromodulative treatment with 
percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes 
following a shortened 6-week protocol, BJU International, vol. 106, no. 11, pp. 1673–
1676, 2010. 
Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder 
symptoms: a multicenter phase III trial. J Urol 2004; 171:2311.  
Zinner N, Susset J, Gittelman M, et al. Efficacy, tolerability and safety of darifenacin, an M(3) 
selective receptor antagonist: an investigation of warning time in patients with 
OAB. Int J Clin Pract 2006; 60:119.  
Zinner N, Kobashi KC, Ebinger U, et al. Darifenacin treatment for overactive bladder in 
patients who expressed dissatisfaction with prior extended-release antimuscarinic 
therapy,” International Journal of Clinical Practice, vol. 62, no.11, pp. 1664–1674, 2008.  
www.intechopen.com
Urinary Incontinence
Edited by Mr. Ammar Alhasso
ISBN 978-953-51-0484-1
Hard cover, 324 pages
Publisher InTech
Published online 04, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Management strategies are framed within a multidisciplinary team structure and as such a range of specialists
ranging from psychologists, specialist nurses, gynaecologists and urologists author the chapters. There are
some novel methods outlined by the authors with their clinical application and utility described in detail, along
with exhaustive research on epidemiology, which is particularly relevant in planning for the future.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Howard A. Shaw and Julia A. Shaw (2012). Diagnosis and Treatment of Overactive Bladder, Urinary
Incontinence, Mr. Ammar Alhasso (Ed.), ISBN: 978-953-51-0484-1, InTech, Available from:
http://www.intechopen.com/books/urinary-incontinence/diagnosis-and-treatment-of-overactive-bladder
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
